Figure 1.
Quantification of plaque characteristics of both early and delayed anti-CD40L antibody- and control-treated apoE−/− mice. (a) Individual plaque area; (b) T-lymphocyte content; (c) macrophage content; (d) lipid core content; (e) collagen content; (f) ASMA content. ∗, P < 0.05, anti-CD40L antibody vs. control; #, P < 0.05, 17-wk control treatment group (age at which delayed treatment started) vs. delayed anti-CD40L antibody treatment group or delayed control treatment group.
